 |
2 Diseases |  |
40 Trials |
|
40 Trials |  |
1659 News |  |
| «12345678910111213...1718» |
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Luspatercept Promotes Heme Biosynthesis and Erythroblast Island Formation in a Novel Low-Risk MDS Mouse Model (Grand Hall D (Manchester Grand Hyatt San Diego)) - Nov 6, 2024 - Abstract #ASH2024ASH_2191;
signaling by luspatercept treatment reverses anemia by promoting heme biosynthesis in EPs and expanding a subset of macrophages for EBI formation. Finally, elucidating the role of MC II in MDS may provide alternative targets that can be combined with the current standard of care HMA and luspatercept therapy tailored for different subtypes and stages of MDS.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts (Halls G-H - Blood Journals Studio (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_1195;
pathway, has the potential to modify the dysregulated immunological microenvironment of LR-MDS. The study is currently ongoing with the purpose of validating these findings in a larger cohort and of exploring their implications in MDS clinical management.
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New P1 trial: Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Oct 31, 2024
P1, N=24, Not yet recruiting, Sponsor: Groupe Francophone des Myelodysplasies
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal, Real-world evidence, Real-world: Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa. (Pubmed Central) - Oct 17, 2024
The effect was particularly high in the IPSS-M low and very low groups. We believe that the relatively high response rate in our patients was influenced by the frequent use of a higher dose (1.75 mg/kg) and especially by adding ESA to luspatercept in poorly responding patients.
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal: Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives. (Pubmed Central) - Oct 17, 2024
We believe that the relatively high response rate in our patients was influenced by the frequent use of a higher dose (1.75 mg/kg) and especially by adding ESA to luspatercept in poorly responding patients. No abstract available
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Biomarker, Trial completion date, Trial primary completion date: AIHA ITP CIN: Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia (clinicaltrials.gov) - Oct 15, 2024
P=N/A, N=200, Recruiting, Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
No abstract available Trial completion date: Jun 2030 --> Jun 2035 | Trial primary completion date: Sep 2026 --> Sep 2030
- |||||||||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Enrollment change, Trial withdrawal, HEOR, Real-world evidence, Real-world: CA056-1083: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 9, 2024
P=N/A, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Trial completion date: Jun 2030 --> Jun 2035 | Trial primary completion date: Sep 2026 --> Sep 2030 Not yet recruiting --> Withdrawn | N=86 --> 0
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Iron Overload in Acquired Sideroblastic Anemias and MDS: Pathophysiology and Role of Chelation and Luspatercept (Room 29 (San Diego Convention Center); Virtual) - Oct 5, 2024 - Abstract #ASH2024ASH_738;
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Luspatercept: A Treatment for Ineffective Erythropoiesis in Thalassemia (Room 30 (San Diego Convention Center); Virtual) - Oct 5, 2024 - Abstract #ASH2024ASH_736;
- Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios (Room 29 (San Diego Convention Center); Virtual) - Oct 5, 2024 - Abstract #ASH2024ASH_732;
The intricate interplay between iron and porphyrin metabolism can be disturbed by inherited or acquired causes. Therapeutic options to mitigate the ensuing clinical symptoms are highlighted by the three speakers of this session.
- Givlaari (givosiran) / Alnylam, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Integrating New Therapies into the Management of Classical Heme Disorders (Room 30 (San Diego Convention Center); Virtual) - Oct 5, 2024 - Abstract #ASH2024ASH_731;
For Dr. Dickey
- MODULE 4: Future Directions in the Management of MF (Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH; In-Person; Virtual) - Oct 5, 2024 - Abstract #ASH2024ASH_130;
Dickey This program is supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation and Karyopharm Therapeutics.Mechanism of antitumor activity of navitoclax and biological rationale for its evaluation for MF Available efficacy and safety findings from the Phase III TRANSFORM-1 study of navitoclax in combination with ruxolitinib versus ruxolitinib alone for patients with previously untreated MF Potential role of navitoclax in the up-front setting and ongoing evaluation for relapsed/refractory (R/R) disease in the Phase III TRANSFORM-2 study Rationale for the evaluation of BET inhibitors for MF; updated findings from the Phase III MANIFEST-2 study combining pelabresib to ruxolitinib for JAK inhibitor-na
- || Venclexta (venetoclax) / Roche, AbbVie, Rytelo (imetelstat) / Geron, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Review, Journal: Targeted therapies for myelodysplastic Syndromes/Neoplasms (MDS): current landscape and future directions. (Pubmed Central) - Oct 5, 2024
Despite some promising results, many therapies remain in early development or have faced setbacks, emphasizing the need for a more comprehensive understanding of the disease's pathobiology. Continued research into targeted therapies, homogenous clinical trial designs, as well as increased incorporation of molecular prognostic tools and artificial intelligence into trial design are essential for developing effective treatments for MDS and improving patient outcomes.
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal: Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes? (Pubmed Central) - Oct 2, 2024
Continued research into targeted therapies, homogenous clinical trial designs, as well as increased incorporation of molecular prognostic tools and artificial intelligence into trial design are essential for developing effective treatments for MDS and improving patient outcomes. No abstract available
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Phase classification: A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Sep 20, 2024
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
No abstract available Phase classification: P1 --> P2
- |||||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New trial, Real-world evidence, Real-world: CA056-1132: A Real-World Study of ?-Thalassemia Major Treatment With Luspatercept in Taiwan (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=90, Recruiting, Sponsor: Bristol-Myers Squibb
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New trial: A clinical study evaluating the efficacy and safety of luspatercept combined with androgen in the treatment of anemia caused by very poor, poor or intermediate risk IPSS-R myelodysplastic syndrome (MDS) (EUDRACT) - Sep 20, 2024
P=N/A, N=16, Recruiting, Sponsor: The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
- | Jakafi (ruxolitinib) / Incyte, Xpovio (selinexor) / Karyopharm, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New P2 trial: Selinexor combined with luspatercept in transfusion-dependent patients with bone marrow fibrosis-associated anemia refractory or intolerant to ruxolitinib: a prospective, multi-center, phase 2 study (EUDRACT) - Sep 20, 2024
P2, N=40, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University; The First Affiliated Hospital with Nanjing
- || Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Enrollment closed: A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (?)-Thalassemia. (clinicaltrials.gov) - Sep 19, 2024
P2, N=90, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P1 --> P2 Recruiting --> Active, not recruiting
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Biomarker, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion-dependent ?-thalassemia. (Pubmed Central) - Sep 12, 2024
Recruiting --> Active, not recruiting No abstract available
- Progress in Lower-Risk MDS () - Aug 30, 2024 - Abstract #SOHO2024SOHO_1041;
Roxadustat, an oral HIF1- alpha hydroxylase inhibitor, was approved for treating anemia in Europe and China for chronic renal insufficiency...Both romiplostim and eltrombopag are approved for treating immune thrombocytopenic purpura, but their use in LR- MDS is still off label...Conclusions Significant progress has been obtained in treating anemia in LR- MDS, but there is still room for improvement by building a strategy to optimize the sequence of therapies with agents with different mechanisms of action and by evaluating combinations of them to achieve long-lasting TI. Target therapies like ivosidenib, a mutant IDH1 inhibitor, could be a candidate for LR-MDS cases with this mutation, as suggested by pivotal studies.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Dramatically Decreased Transfusion Dependency With Luspatercept in a Case of High-Risk MDS (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_601;
Repeat bone marrow biopsy showed persistent MDS with myelofibrosis and he was switched to ruxolitinib...Further, the COMMAND trial showed superiority of luspatercept in RBC transfusion dependence compared to erythropoietin alpha in ESA-naive patients with low-risk MDS with or without ringed sideroblasts. The substantial advantage that our patient with high-risk MDS exhibited after starting luspatercept suggests that patients with high-risk MDS should also be evaluated for this novel drug, and further trials can be done to evaluate for efficacy and quality-of-life improvement in this patient population.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Myelodysplastic syndromes with concomitant SF3B1 mutation and deletion of the long arm of chromosome 5 (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_584;
The mOS of 66 months for concomitant del(5q)/ SF3B1 is still inferior to the isolated entities. Our data suggest that Len should be first-line therapy for those patients followed by Luspa and HMA.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_578;
Rates of ESA failure were high overall and within key subgroups by RS status and EPO level. Most patients had no transfusions in the 8 weeks prior to treatment, suggesting ESAs may not be effective at increasing Hb levels in patients with LR-MDS.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_576;
An EMR alert resulted in a higher proportion of patients being appropriately dosed with luspatercept and enabled >80% to reach maximum dose/ achieve RBC-TI. EMR interventions may enhance appropriateness of luspatercept treatment, improving patient outcomes.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Real World Efficacy of Luspatercept in Patients with Lower-risk Myelodysplastic Syndromes/Neoplasms (LR-MDS); a Single Center Study in a Heavily Pretreated Cohort (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_575;
Dose escalation restored TI in 50% who lost response at submaximal dosages. Response was associated with EPO <100 mU/mL, but not with baseline transfusion burden.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_573;
P3
Response was associated with EPO <100 mU/mL, but not with baseline transfusion burden. Luspatercept versus EA led to demonstrable improvements in erythroid, neutrophil, and platelet lineages, supporting its use in patients with ESA-naive, TD LRMDS.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_572;
P3
Luspatercept versus EA led to demonstrable improvements in erythroid, neutrophil, and platelet lineages, supporting its use in patients with ESA-naive, TD LRMDS. More luspatercept versus EA patients achieved hemoglobin level improvements, reductions in transfusion burden and RBC units transfused, and had durable RBC-TI responses, supporting luspatercept use as the preferred treatment for ESA-naive patients with LR-MDS
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Real-World Impact of Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) on the Healthcare Resource Utilization (HRU) of Patients With Myelodysplastic Syndromes (MDS) in the United States (US) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_569;
More luspatercept versus EA patients achieved hemoglobin level improvements, reductions in transfusion burden and RBC units transfused, and had durable RBC-TI responses, supporting luspatercept use as the preferred treatment for ESA-naive patients with LR-MDS This study found luspatercept was associated with a statistically significant reduction in HRU compared with ESA treatments.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
TGF-? Signaling-Mediated Upregulation of Podoplanin: A Promising Biomarker for Diagnosis and Prognosis in Acute Promyelocytic Leukemia (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_397;
This study found luspatercept was associated with a statistically significant reduction in HRU compared with ESA treatments. Our findings suggest PDPN as a potential diagnostic biomarker that could serve as a putative prognostic marker and therapeutic target in APL.
- |||||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New trial, HEOR, Real-world evidence, Real-world: CA056-1083: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Aug 30, 2024
P=N/A, N=86, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date: A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or ?-thalassemia (clinicaltrials.gov) - Aug 27, 2024
P=N/A, N=104, Recruiting, Sponsor: Bristol-Myers Squibb
Our findings suggest PDPN as a potential diagnostic biomarker that could serve as a putative prognostic marker and therapeutic target in APL. Trial completion date: Sep 2029 --> Dec 2027 | Initiation date: Nov 2023 --> Mar 2024 | Trial primary completion date: Dec 2028 --> Dec 2027
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal: Luspatercept for non-deletional hemoglobin H disease. (Pubmed Central) - Aug 23, 2024
Trial completion date: Sep 2029 --> Dec 2027 | Initiation date: Nov 2023 --> Mar 2024 | Trial primary completion date: Dec 2028 --> Dec 2027 No abstract available
- |||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New P1/2 trial: A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA (EUDRACT) - Aug 13, 2024
P1/2, N=150, Ongoing, Sponsor: Groupe Francophone des My
- ||||| Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Enrollment closed: INDEPENDENCE: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (clinicaltrials.gov) - Aug 9, 2024
P3, N=309, Active, not recruiting, Sponsor: Celgene
No abstract available Recruiting --> Active, not recruiting
- Mycamine (micafungin) / Astellas, Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
FUNGUS AMONG US: A CASE OF INVASIVE ASPERGILLOSIS CAUSING POSTERIOR MEDIASTINITIS AND THORACIC MYELITIS (Convention Center Exhibit Hall: Rapid Fire Area 1D) - Jul 31, 2024 - Abstract #CHEST2024CHEST_4565;
Neutropenia prophylaxis included acyclovir and dapsone... Healthcare providers caring for neutropenic patients should be aware of posterior mediastinitis and myelitis as unusual presentations of invasive aspergillosis to allow for expeditious diagnosis and initiation of appropriate therapies.
- |||| Ojjaara (momelotinib) / GSK
New P2 trial, Combination therapy: ODYSSEY: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (clinicaltrials.gov) - Jul 24, 2024
P2, N=56, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Jakafi (ruxolitinib) / Incyte, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New trial: A dose-exploration clinical study evaluating the combination of Ruxolitinib and luspatercept in the treatment of myelofibrotic anemia in subjects (EUDRACT) - Jul 15, 2024
P=N/A, N=18, Recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New P3 trial: Clinical study of low-dose decitabine with granulocyte stimulating factor combined with Luspatercept to prevent relapse after high-risk acute myeloid leukemia transplantation (EUDRACT) - Jul 15, 2024
P3, N=102, Not yet recruiting, Sponsor: Xinqiao Hospital of Army Medical University; Xinqiao Hospital of Army Medical University
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal: Luspatercept enhances hemoglobin levels in a Chinese boy with congenital sideroblastic anemia: A case report. (Pubmed Central) - Jul 12, 2024
Healthcare providers caring for neutropenic patients should be aware of posterior mediastinitis and myelitis as unusual presentations of invasive aspergillosis to allow for expeditious diagnosis and initiation of appropriate therapies. We believe that luspatercept might emerge as a viable therapeutic option for the maintenance treatment of CSA or as a bridging treatment option before hematopoietic stem cell transplantation.
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
MDS/MPN Overlap Syndromes (Level 3, 370 AD) - Jul 5, 2024 - Abstract #SOHO2024SOHO_24;
Moreover, MDS/MPN overlap syndromes can have concomitant synchronous malignancies that could include lymphoid neoplasms and mastocytosis. This presentation will address these challenges, summarize the advances that have been made in these areas, and discuss important future directions for the diagnosis and management of patients with overlap syndromes.
- || Rytelo (imetelstat) / Geron, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Review, Journal: Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome. (Pubmed Central) - Jul 3, 2024
For those without previous luspatercept exposure it can be considered particularly if there is an SF3B1 mutation or the presence of ring sideroblasts. Other options include HMAs or IST; the Phase III IMERGE trial supports the efficacy of the telomerase inhibitor imetelstat in this setting and this may become a standard option in the future as well.
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal: Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study. (Pubmed Central) - Jun 22, 2024
No patients had died by the end of follow-up. Luspatercept induced a good response in patients with anemic myelofibrosis, with a low relapse rate and good tolerance.
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal: Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. (Pubmed Central) - May 31, 2024
P2
In patients with myelofibrosis, luspatercept improved anemia and transfusion burden across cohorts; the safety profile was consistent with previous studies. NCT03194542 clinicaltrials.gov.
- || Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Trial completion date, Trial primary completion date: Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms (clinicaltrials.gov) - May 28, 2024
P2, N=70, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT03194542 clinicaltrials.gov. Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
- || Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Review, Journal: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities. (Pubmed Central) - May 25, 2024
Lower-risk MDS (LR-MDS) treatment ranges from observation to supportive measures and erythropoiesis-stimulating agents (ESAs), with emerging therapies like luspatercept showing promise...Emerging treatments, including oral HMAs and novel agents targeting FLT3, and IDH 1/2 mutations, show promise. Future research should refine treatment strategies for this elderly population focusing on quality-of-life improvement.
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New P4 trial: Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA (clinicaltrials.gov) - May 22, 2024
P4, N=58, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal: New partners for Luspatercept in ?-thalassemia. (Pubmed Central) - May 16, 2024
Future research should refine treatment strategies for this elderly population focusing on quality-of-life improvement. No abstract available
- || Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Review, Journal: Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies. (Pubmed Central) - Apr 29, 2024
This review summarizes the historical impact of luspatercept intreating LR-MDS unresponsive to ESAs and illustrates its potential benefit asfrontline therapy in MDS and its employment in patients with myelofibrosis-induced anemia. Luspatercept has revolutionized the therapeutic paradigm of LR-MDS, for which there was a limited therapeutic arsenal, especially in the setting of patients who did not respond or fail after ESA treatment.
- || Promacta (eltrombopag) / Novartis, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Review, Journal: Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms. (Pubmed Central) - Apr 27, 2024
Recent advancements in genomic profiling have provided valuable insights into the biological underpinnings of MDSs and have expanded therapeutic options, particularly for specific molecularly defined subgroups. This review highlights the diagnostic principles, classification updates, prognostic stratification systems, and novel treatments, which could inform future clinical trials and enhance the management of adult MDS patients, particularly for specific molecularly defined subgroups.